| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -27,077 | -14,919 |
| Change in fair value of royalty monetization liability | 0 | 0 |
| Unrealized loss (gain) on equity investments | -66 | -66 |
| Change in accrued interest and accretion of discount on marketable securities | -433 | -322 |
| Stock-based compensation expense | 3,612 | 2,503 |
| Depreciation and amortization expense | 256 | 240 |
| Noncash operating lease expense | 882 | 582 |
| Change in lease liability | -994 | -657 |
| Prepaid expenses and other current assets | 356 | 878 |
| Accounts payable | -1,480 | 760 |
| Accrued expenses | -3,120 | -3,147 |
| Deferred revenue | 718 | 718 |
| Net cash used in operating activities | -27,926 | -15,054 |
| Purchase of marketable securities | 14,792 | 9,845 |
| Sales/maturities of marketable securities | 37,000 | 27,000 |
| Purchases of property and equipment | 0 | 0 |
| Software development and other costs | 0 | 0 |
| Net cash provided by investing activities | 22,208 | 17,155 |
| Proceeds from exercise of options and purchases from employee stock purchase plan | 28 | 13 |
| Net cash provided by financing activities | 28 | 13 |
| Net decrease in cash, cash equivalents and restricted cash | -5,690 | 2,114 |
| Cash and cash equivalents at beginning of period | 28,232 | - |
| Cash and cash equivalents at end of period | 22,542 | - |
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)